2-Chlorodeoxyadenosine to Treat Refractory Histiocytosis X
- 2 September 1993
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 329 (10), 734-735
- https://doi.org/10.1056/nejm199309023291013
Abstract
Treatment of histiocytosis X is palliative at best. It includes corticosteroids, alkylating agents, antimetabolites, vinca alkaloids, and irradiation1. Since 2-chlorodeoxyadenosine, a purine substrate analogue active against lymphoid cancers,2 is toxic to monocytes in vitro,3 and since tissue histiocytes are derived from circulating monocytes as they move from the intravascular space to soft tissues, we administered 2-chlorodeoxyadenosine to a patient with histiocytosis X.Keywords
This publication has 3 references indexed in Scilit:
- 2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive NucleosideLeukemia & Lymphoma, 1991
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.JCI Insight, 1990
- Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.JCI Insight, 1985